Meral Beksac
Meral Beksac
Verified email at
Cited by
Cited by
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
SV Rajkumar, MA Dimopoulos, A Palumbo, J Blade, G Merlini, MV Mateos, ...
The lancet oncology 15 (12), e538-e548, 2014
International uniform response criteria for multiple myeloma
BGM Durie, JL Harousseau, JS Miguel, J Blade, B Barlogie, K Anderson, ...
Leukemia 20 (9), 1467-1473, 2006
Daratumumab, bortezomib, and dexamethasone for multiple myeloma
A Palumbo, A Chanan-Khan, K Weisel, AK Nooka, T Masszi, M Beksac, ...
New England Journal of Medicine 375 (8), 754-766, 2016
Elotuzumab therapy for relapsed or refractory multiple myeloma
S Lonial, M Dimopoulos, A Palumbo, D White, S Grosicki, I Spicka, ...
New England Journal of Medicine 373 (7), 621-631, 2015
Continuous lenalidomide treatment for newly diagnosed multiple myeloma
A Palumbo, R Hajek, M Delforge, M Kropff, MT Petrucci, J Catalano, ...
New England Journal of Medicine 366 (19), 1759-1769, 2012
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a …
JF San-Miguel, VTM Hungria, SS Yoon, M Beksac, MA Dimopoulos, ...
The lancet oncology 15 (11), 1195-1206, 2014
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders
AC Rawstron, A Orfao, M Beksac, L Bezdickova, R Brooimans, H Bumbea, ...
haematologica 93 (3), 431-438, 2008
The shaping of modern human immune systems by multiregional admixture with archaic humans
L Abi-Rached, MJ Jobin, S Kulkarni, A McWhinnie, K Dalva, L Gragert, ...
Science 334 (6052), 89-94, 2011
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3
M Dimopoulos, R Kyle, JP Fermand, SV Rajkumar, J San Miguel, ...
Blood, The Journal of the American Society of Hematology 117 (18), 4701-4705, 2011
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a …
M Attal, PG Richardson, SV Rajkumar, J San-Miguel, M Beksac, I Spicka, ...
The Lancet 394 (10214), 2096-2107, 2019
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)
A Palumbo, S Bringhen, H Ludwig, MA Dimopoulos, J Bladé, MV Mateos, ...
Blood, The Journal of the American Society of Hematology 118 (17), 4519-4529, 2011
International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma
M Dimopoulos, E Terpos, RL Comenzo, P Tosi, M Beksac, O Sezer, ...
Leukemia 23 (9), 1545-1556, 2009
International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment
MA Dimopoulos, P Sonneveld, N Leung, G Merlini, H Ludwig, E Kastritis, ...
Journal of Clinical Oncology 34 (13), 1544-1557, 2016
European Myeloma Network guidelines for the management of multiple myeloma-related complications
E Terpos, M Kleber, M Engelhardt, S Zweegman, F Gay, E Kastritis, ...
haematologica 100 (10), 1254, 2015
Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials
PM Fayers, A Palumbo, C Hulin, A Waage, P Wijermans, M Beksaç, ...
Blood, The Journal of the American Society of Hematology 118 (5), 1239-1247, 2011
Management of treatment-emergent peripheral neuropathy in multiple myeloma
PG Richardson, M Delforge, M Beksaç, P Wen, JL Jongen, O Sezer, ...
Leukemia 26 (4), 595-608, 2012
Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia
N Schmitz, M Beksac, D Hasenclever, A Bacigalupo, T Ruutu, A Nagler, ...
Blood, The Journal of the American Society of Hematology 100 (3), 761-767, 2002
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label …
PG Richardson, A Oriol, M Beksac, AM Liberati, M Galli, F Schjesvold, ...
The Lancet Oncology 20 (6), 781-794, 2019
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
SK Kumar, MA Dimopoulos, E Kastritis, E Terpos, H Nahi, H Goldschmidt, ...
Leukemia 31 (11), 2443-2448, 2017
IMWG consensus on maintenance therapy in multiple myeloma
H Ludwig, BGM Durie, P McCarthy, A Palumbo, J San Miguel, B Barlogie, ...
Blood, The Journal of the American Society of Hematology 119 (13), 3003-3015, 2012
The system can't perform the operation now. Try again later.
Articles 1–20